Prosecution Insights
Last updated: November 15, 2026

Create Medicines Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Create Medicines Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 4 art units, indicating a separate examination channel for each pending matter. That structure calls for individualized response planning and careful tracking of each examiner's treatment.

LI, RUIXIANG is the busiest examiner, with 1 pending matter. No identified examiner carries more than that pending matter, so the profile does not show a dominant examiner relationship. Counsel can still use common scientific and claim themes, but amendments should be tied to the relevant art unit and record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (25%)
2
Medium (50%)
1
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§102 only1 (25%)
§112 only1 (25%)
Multi-statute (no §101)1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LI, RUIXIANG 1 59.5% +18.7%
LANDSMAN, ROBERT S 1 81.4% +13.0%
PENNINGTON, KATIE LEIGH 1 32.4% +60.2%
VIVLEMORE, TRACY ANN 1 72.7% +6.8%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18420382 CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER LANDSMAN, ROBERT S 14d

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17837093 THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF VIVLEMORE, TRACY ANN 28d

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18420382 CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER LANDSMAN, ROBERT S 14d
18674029 ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF LI, RUIXIANG —
18313087 METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION PENNINGTON, KATIE LEIGH —

Top Art Units

Art UnitApps
1674 1
1647 1
1634 1
1638 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18674029 ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF LI, RUIXIANG 1674 §102Other Non-Final OA — Pending May 24, 2024
18420382 CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER LANDSMAN, ROBERT S 1647 §103Other Final Rejection 14d Pending Jan 23, 2024
18313087 METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION PENNINGTON, KATIE LEIGH 1634 §112 Final Rejection — Pending May 05, 2023
17837093 THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF VIVLEMORE, TRACY ANN 1638 §103§112 Non-Final OA 28d Pending Jun 10, 2022

Managing Create Medicines Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Create Medicines Inc. have?

Create Medicines Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Create Medicines Inc. applications?

Ruixiang Li has the most, with 1 of Create Medicines Inc.'s pending office actions.

What technology area are Create Medicines Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month